The ASCO Post Staff
/
Monday, June 30, 2025 11:00 AM
About one in six tested chemotherapies in sub-Saharan Africa were found to have serious quality defects, according to the results of a study published in The Lancet Global Health.
Researchers assessed the appearance, packaging, and labeling of each cancer medication and measured the quantity of...
Matthew Stenger
/
Monday, June 30, 2025 11:22 AM
As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...
Matthew Stenger
/
Thursday, April 3, 2025 10:56 AM
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper tract urothelial carcinoma.
Study Details
In this multicenter open-label trial, 45...
Matthew Stenger
/
Tuesday, April 8, 2025 11:21 AM
In a U.S. population–based cohort study reported in JAMA Network Open, Bari et al identified patterns of immune checkpoint inhibitor (ICI) use and survival outcomes among patients with metastatic colorectal cancer seen in routine clinical practice.
The investigators stated: “…ICIs have been...
EMRE YEKEDÜZ, MD, AND YÜKSEL ÜRÜN, MD
/
Monday, June 30, 2025 12:29 PM
The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting.
Kidney Cancer: Long-Term...
Matthew Stenger
/
Thursday, April 10, 2025 11:44 AM
In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality.
Study Details
In the multicenter study, eligible...
The ASCO Post Staff
/
Tuesday, April 15, 2025 11:54 AM
The incidence rates of colorectal and pancreatic adenocarcinomas have risen the most among young adults over the past 2 decades, suggesting the need for heightened awareness among clinicians for these diseases in this patient population, according to a report published by Bussetty et al in JAMA...
The ASCO Post Staff
/
Wednesday, April 23, 2025 11:52 AM
Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer, according to a recent study published by Moussa et al in Cancer Prevention Research.
Background
Ellagitannins—plant-derived polyphenol compounds found in walnuts—have been...
The ASCO Post Staff
/
Friday, April 25, 2025 10:27 AM
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
Jo Cavallo
/
Monday, April 28, 2025 11:30 AM
Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The...
The ASCO Post Staff
/
Thursday, May 1, 2025 10:00 AM
A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halved deaths, and brought racial differences in outcomes to nearly zero, according to a study that will ...
The ASCO Post Staff
/
Thursday, May 1, 2025 11:50 AM
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology.
The 5-year mortality rate in patients with a...
The ASCO Post Staff
/
Tuesday, May 6, 2025 2:32 PM
Five pivotal studies presented at ESTRO 2025 showcase how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations offer safer, more effective, and organ-preserving...
The ASCO Post Staff
/
Thursday, May 15, 2025 6:01 PM
On May 15, the U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)....
The ASCO Post Staff
/
Friday, May 16, 2025 10:15 AM
Total neoadjuvant therapy of intensified chemoradiotherapy was shown to be less effective for treating patients with rectal cancer with inflammatory bowel disease (IBD) than those with sporadic rectal cancer, according to study findings presented during Digestive Disease Week 2025. However, there...
Matthew Stenger
/
Monday, May 19, 2025 10:19 AM
In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus.
Study Details
In the ...
The ASCO Post Staff
/
Tuesday, May 27, 2025 11:45 AM
An evaluation by the Department of Justice Office of the Inspector General (DOJ OIG) of the Federal Bureau of Prisons’ (BOP) colorectal cancer screening practices for inmates and their clinical follow-up for positive screenings found several serious operational and managerial deficiencies...
The ASCO Post Staff
/
Friday, May 30, 2025 10:00 AM
Universal germline testing is essential for identifying hereditary cancer risk, especially for patients with young-onset colorectal cancer who were diagnosed before the age of 50. However, the implementation of universal germline testing has been hampered by increasing demand and limited physician...
The ASCO Post Staff
/
Friday, May 30, 2025 12:29 PM
Results from an international phase III study showed that the targeted therapy combination of encorafenib and cetuximab with mFOLFOX6 (leucovorin, fluorouracil, and oxaliplatin) chemotherapy may help patients with BRAF V600E–mutant metastatic colorectal cancer live longer. After early results from...
The ASCO Post Staff
/
Sunday, June 1, 2025 10:18 AM
Results from the international phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy experience a 50% reduction in disease recurrence or death compared with chemotherapy alone. The findings...
Jo Cavallo
/
Sunday, June 1, 2025 12:57 PM
A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II...
Matthew Stenger
/
Monday, June 30, 2025 10:00 AM
In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Study Details
In the...
The ASCO Post Staff
/
Wednesday, June 4, 2025 10:37 AM
Marital status significantly impacts survival rates for patients with colorectal cancer, according to a new Fox Chase Cancer Center study that was presented at the 2025 ASCO Annual Meeting (Abstract 3628). Married individuals were found to have better survival rates than single or separated and...
The ASCO Post Staff
/
Wednesday, June 4, 2025 12:45 PM
Consuming an anti-inflammatory diet could improve posttreatment survival among patients with colorectal cancer compared with following a proinflammatory diet, according to new findings presented by Char et al at the 2025 ASCO Annual Meeting (Abstract LBA3509). The findings suggested that engaging...
Matthew Stenger
/
Monday, June 30, 2025 11:31 AM
In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...
Matthew Stenger
/
Friday, June 13, 2025 10:27 AM
In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al compared short-term response rates with standard- vs reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus.
Study Details
In the multicenter, open-label, noncomparative trial,...
The ASCO Post Staff
/
Friday, June 13, 2025 11:20 AM
Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology.
"Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...
The ASCO Post Staff
/
Wednesday, June 18, 2025 10:40 AM
The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...
The ASCO Post Staff
/
Friday, June 27, 2025 10:54 AM
Researchers have uncovered a biomarker that may determine response to cytokine-induced killer-cell therapy and survival in patients with colorectal cancer, according to a recent study published by Li et al in The Journal of Immunology.
Background
Colorectal cancer is the second-leading cause of...
The ASCO Post Staff
/
Monday, June 30, 2025 10:51 AM
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The...
The ASCO Post Staff
/
Monday, January 29, 2024 11:21 AM
The phase III KEYNOTE-564 study has reported that adjuvant pembrolizumab provides a significant improvement in overall survival for patients with clear cell renal cell carcinoma at high risk of recurrence after surgery. This study is significant, as it represents the first phase III study to show...
The ASCO Post Staff
/
Tuesday, January 30, 2024 10:14 AM
Immune checkpoint inhibitor–based therapy may be an equally effective front-line treatment in both Black and White patients with metastatic renal cell carcinoma, according to recent findings presented by Kaur et al at the 2024 ASCO Genitourinary Cancers Symposium (Abstract 369).
Background
Race may ...
Alice Goodman
/
Tuesday, January 30, 2024 12:49 PM
In previously treated patients with advanced or metastatic clear cell renal cell carcinoma, a subcutaneous formulation of nivolumab was found to be noninferior to the intravenous formulation, which is standard of care for nivolumab in renal cell carcinoma and other cancers. Compared with...
Matthew Stenger
/
Monday, April 1, 2024 12:20 PM
As reported in the Journal of Clinical Oncology by Leonard J. Appleman, MD, PhD, and colleagues, the phase II ECOG-ACRIN E2810 trial showed no significant improvement in disease-free survival with pazopanib vs placebo in patients with metastatic renal cell carcinoma with no evidence of disease...
The ASCO Post Staff
/
Tuesday, April 9, 2024 10:17 AM
The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...
Matthew Stenger
/
Friday, April 26, 2024 12:04 PM
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, and colleagues, the third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in patients with clear cell renal...
The ASCO Post Staff
/
Wednesday, May 8, 2024 10:27 AM
Researchers have identified novel biomarkers in renal cell carcinoma subtypes, according to a new study published by Li et al in Cell Reports Medicine. The findings may help identify therapeutic targets in non–clear cell renal cell carcinomas.
Background
Renal cell carcinoma is a diverse cancer...
The ASCO Post Staff
/
Thursday, May 9, 2024 10:23 AM
The novel investigational positron-emission tomography (PET) imaging agent gallium (Ga)-68–DPI-4452 may offer rapid and accurate visualization of lesions in patients with clear cell renal cell carcinoma, according to a recent study published by Hofman et al in The Journal of Nuclear Medicine. The...
Matthew Stenger
/
Wednesday, May 15, 2024 12:16 PM
In a study reported in the Journal of Clinical Oncology, Xu et al found that higher levels of preoperative plasma kidney injury molecule-1 (pKIM-1) distinguished renal cell carcinoma from benign renal masses.
As stated by the investigators, “Both clear cell and papillary renal cell carcinoma...
Matthew Stenger
/
Thursday, June 20, 2024 11:49 AM
As reported in the Journal of Clinical Oncology by Nizar M. Tannir, MD, FACP, and colleagues, the phase III PIVOT-09 trial has shown no objective response or overall survival benefit with bempegaldesleukin plus nivolumab vs tyrosine kinase inhibitor (TKI) treatment with sunitinib or cabozantinib in ...
The ASCO Post Staff
/
Thursday, June 27, 2024 10:56 AM
Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology.
Background
Approximately 3% to 5% of all cancer diagnoses ...
Matthew Stenger
/
Tuesday, July 2, 2024 11:25 AM
As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma.
Study
...
Matthew Stenger
/
Tuesday, August 27, 2024 1:11 PM
In a subgroup analysis of the EVEREST trial reported in JAMA Network Open, Gulati et al found that adjuvant everolimus did not improve recurrence-free survival vs placebo in patients with localized papillary or chromophobe non–clear cell renal cell carcinoma (RCC).
Study Details
In the trial,...
Matthew Stenger
/
Wednesday, September 4, 2024 10:38 AM
As reported in The New England Journal of Medicine by Choueiri and colleagues, the phase III LITESPARK-005 trial has shown improved progression-free survival with the hypoxia-inducible factor–2α inhibitor belzutifan vs everolimus in previously treated patients with advanced clear-cell renal cell...
The ASCO Post Staff
/
Friday, November 10, 2023 2:24 PM
On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
Caroline Helwick
/
Monday, November 13, 2023 11:02 AM
Early findings from the phase II EDGE-Gastric trial indicate the potential for two novel agents to make a difference in advanced gastroesophageal adenocarcinoma, according to findings reported at the ASCO Plenary Series: November 2023 Session by Yelena Y. Janjigian, MD, Chief of the...
Matthew Stenger
/
Thursday, January 4, 2024 12:23 PM
As reported in The Lancet Oncology by Kohei Shitara, MD, and colleagues, interim analyses of the phase III KEYNOTE-585 trial have shown that the addition of perioperative pembrolizumab to chemotherapy improved pathologic complete response, but did not significantly improve event-free survival, in...
Caroline Helwick
/
Wednesday, January 24, 2024 12:21 PM
Subgroup analyses of the randomized double-blind phase III MATTERHORN trial continue to show the benefit of adding perioperative durvalumab to standard chemotherapy in patients with locally advanced, resectable gastric or gastroesophageal junction cancer. Detailed findings on pathologic complete...
Chase Doyle
/
Wednesday, February 7, 2024 12:45 PM
The combination of fruquintinib and paclitaxel is a potential new second-line treatment for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: February 2024 Session (Abstract 438780).
Results of the phase III FRUTIGA...
Matthew Stenger
/
Tuesday, February 27, 2024 1:37 PM
As reported in the Journal of Clinical Oncology by Yelena Y. Janjigian, MD, and colleagues, 3-year follow-up of the phase III CheckMate 649 trial has shown the continued benefit of the addition of nivolumab to chemotherapy in the first-line treatment of advanced gastric, gastroesophageal junction,...
Matthew Stenger
/
Thursday, March 7, 2024 11:35 AM
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast or gastrointestinal cancer who were ...
The ASCO Post Staff
/
Tuesday, April 9, 2024 10:32 AM
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...
Matthew Stenger
/
Monday, April 29, 2024 10:59 AM
In a French noncomparative phase II trial (PRODIGE 59-FFCD 1707-DURIGAST) reported in JAMA Oncology, Tougeron et al found limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-line treatment of advanced...
The ASCO Post Staff
/
Tuesday, April 30, 2024 12:25 PM
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinoma.
Trastuzumab-strf is indicated for adjuvant treatment of...
Matthew Stenger
/
Tuesday, May 21, 2024 10:29 AM
In the phase II RELATIVITY-060 study, results of which were reported in the Journal of Clinical Oncology, Susanna Hegewisch-Becker, MD, PhD, and colleagues found that the addition of the LAG-3–blocking antibody relatlimab to first-line nivolumab plus chemotherapy did not improve the objective...
Julia Cipriano, MS
/
Friday, June 14, 2024 11:45 AM
As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...
The ASCO Post Staff
/
Tuesday, July 9, 2024 10:11 AM
Targeting lactate with the epilepsy drug stiripentol may reverse chemotherapy resistance in patients with gastric cancer, according to a recent study published by Chen et al in Nature.
Background
Chemotherapy attacks cancer cells by damaging their DNA. The cancer cells then try to rapidly repair...
Matthew Stenger
/
Monday, August 12, 2024 12:57 PM
In a long-term follow-up of a French phase III trial (BFR14) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues found that discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors (GIST) with at least stable disease was associated with markedly poorer...
Julia Cipriano, MS
/
Friday, August 23, 2024 11:18 AM
Based on a descriptive, U.S. population–based cohort study reported in JAMA Network Open by Alvarez et al, over the past 2 decades, the incidence of gastrointestinal stromal tumors in major organ sites has increased among several patient populations. The findings may assist in directing future...
Matthew Stenger
/
Monday, October 21, 2024 12:48 PM
As reported in the Journal of Clinical Oncology by Pavlakis et al, the phase III INTEGRATE IIa study showed improved overall survival with regorafenib plus best supportive care vs placebo vs best supportive care in patients with refractory advanced gastric/esophagogastric junction cancer.
Study...
The ASCO Post Staff
/
Tuesday, December 3, 2024 12:33 PM
New research may expand on existing evidence that a healthy diet may protect against gastrointestinal cancers and improve disease outcomes, according to a recent study published by Abebe et al in the European Journal of Nutrition.
Background
Gastrointestinal cancers including esophageal, gastric,...
Matthew Stenger
/
Tuesday, January 14, 2025 9:04 PM
In a Chinese phase I trial (KYM901) reported in The Lancet Oncology, Ruan et al found that CMG901—a first-in-class claudin 18.2–targeting antibody-drug conjugate—had manageable toxicity and activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. CMG901 comprises a...
The ASCO Post Staff
/
Friday, January 17, 2025 10:05 AM
The risk of having children who experience preterm birth and low birth weight—but not birth defects—may be increased among male adolescents and young adults with cancer, according to a recent study published by Murphy et al in the Journal of the National Cancer Institute.
Background
Prior research...
The ASCO Post Staff
/
Tuesday, January 21, 2025 5:00 PM
A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some types of neuroendocrine tumors in the pancreas or gastrointestinal tract. The research will be...
The ASCO Post Staff
/
Tuesday, February 11, 2025 9:54 AM
Investigators may have uncovered notable pharmacokinetic differences between male and female patients in at least 14 anticancer drugs, according to a recent study published by Delahousse et al in ESMO Open.
Background
Many cancer drugs have a narrow therapeutic window. As a result, slight...
Matthew Stenger
/
Wednesday, February 19, 2025 5:29 PM
As reported in The Lancet Oncology by Zhang et al, final outcomes of the Chinese phase III RESOLVE trial showed improved overall survival with adjuvant S-1 and oxaliplatin (SOX) and perioperative SOX vs adjuvant capecitabine/oxaliplatin (CapOx) in patients with locally advanced gastric or...
The ASCO Post Staff
/
Thursday, February 27, 2025 10:01 AM
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in...
The ASCO Post Staff
/
Thursday, February 27, 2025 11:25 AM
Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option.
Background
Gastric cancer is the fourth...
Jo Cavallo
/
Wednesday, March 5, 2025 10:02 AM
A study evaluating the genetic landscape of candidate primary resistance alterations relevant to KRAS targeting in KRAS G12C–mutant colorectal cancers and pancreatic ductal adenocarcinomas (PDAC) has found that putative resistance alterations are prevalent in these cancers. The finding may explain...
The ASCO Post Staff
/
Thursday, March 20, 2025 9:00 AM
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the PD-L1 inhibitor pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic...
Matthew Stenger
/
Tuesday, April 1, 2025 10:22 AM
In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survival among patients with esophageal cancer who had a clinical complete response after neoadjuvant...
The ASCO Post Staff
/
Thursday, May 1, 2025 10:00 AM
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
The ASCO Post Staff
/
Monday, May 5, 2025 11:48 AM
Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study presented at Digestive Disease Week 2025 (Abstract 76) found. According to the investigators, this shift challenges assumptions about high-risk...
The ASCO Post Staff
/
Monday, May 5, 2025 12:36 PM
Cancer-related studies were among the nearly 6,000 abstracts presented at Digestive Disease Week® (DDW) 2025, including research on artificial intelligence (AI) in patient communication, polyp detection, and colonoscopy prep.
Use of AI in Patient Communication
AI outperformed physicians in...
Matthew Stenger
/
Wednesday, May 14, 2025 11:12 AM
In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al found that a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (docetaxel, folinic acid, oxaliplatin, and fluorouracil) improved outcomes vs FOLFOX (folinic acid,...
The ASCO Post Staff
/
Wednesday, June 11, 2025 12:01 PM
A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...
Matthew Stenger
/
Friday, June 13, 2025 10:36 AM
In a Japanese phase III trial (RINDBeRG) reported in the Journal of Clinical Oncology, Sakai et al assessed whether the addition of ramucirumab to irinotecan would improve overall survival in third- or later-line treatment of patients with advanced or recurrent gastric or gastroesophageal cancer...
Lisa Astor
/
Monday, June 16, 2025 12:06 PM
Patients with gastrointestinal cancer treated with fluoropyrimidine chemotherapy benefit from an almost eightfold reduction in the risk of all-cause mortality, despite a slight increase in the risk for cardiovascular toxicity, according to recent findings published by Abiodun et al in JACC:...
The ASCO Post Staff
/
Thursday, June 19, 2025 4:08 PM
In the United States, approximately 55% of patients with resected gallbladder cancer undergo oncologic surgery without additional systemic treatment. However, as gallbladder cancer progresses to T3 (locally or regionally advanced) or T4 (distant metastasis) disease, the tumor frequently infiltrates ...
The ASCO Post Staff
/
Wednesday, February 12, 2025 10:30 AM
Short-course, higher-dose vaginal brachytherapy for endometrial cancer may demonstrate comparable efficacy to more frequent, lower-dose sessions, according to a recent study published by Suneja et al in JCO Oncology Advances.
Background
Endometrial cancer is the most common cancer type of the...
Matthew Stenger
/
Thursday, February 13, 2025 11:08 AM
In an article in The Lancet Oncology, Oza et al presented the final overall survival analysis of the phase III ARIEL trial of rucaparib vs standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma.
Study Details
In the open-label trial, 349 patients from sites in 12...
The ASCO Post Staff
/
Friday, February 14, 2025 12:36 PM
The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research.
Background
There are over 10,000 ovarian cancer–related deaths in the United...
The ASCO Post Staff
/
Tuesday, February 25, 2025 9:28 PM
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
Matthew Stenger
/
Thursday, February 27, 2025 9:42 AM
In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...
The ASCO Post Staff
/
Thursday, March 6, 2025 10:56 AM
Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology.
Background
Prostate cancer...
Matthew Stenger
/
Wednesday, February 19, 2025 11:06 AM
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs).
As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Matthew Stenger
/
Tuesday, March 11, 2025 10:45 AM
In an Italian single-center phase II trial (RADIOSA) reported in The Lancet Oncology, Marvaso et al found that the addition of androgen-deprivation therapy (ADT) to stereotactic body radiotherapy (SBRT) improved progression-free survival in patients with hormone-sensitive oligorecurrent prostate...
The ASCO Post Staff
/
Wednesday, March 5, 2025 10:14 AM
A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
Julia Cipriano, MS
/
Thursday, March 13, 2025 12:41 PM
Recent findings from the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT), which were published by Gargano et al in the Morbidity and Mortality Weekly Report, revealed decreased incidences of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ lesions among young women.
...
Matthew Stenger
/
Wednesday, March 12, 2025 9:47 AM
As reported in the Journal of Clinical Oncology by Petrylak et al, the phase III KEYNOTE-921 trial showed no benefit in outcomes with the addition of pembrolizumab to docetaxel in patients with previously treated metastatic castration-resistant prostate cancer.
Study Details
In the global...
The ASCO Post Staff
/
Wednesday, March 19, 2025 9:58 AM
Erectile dysfunction could be improved through regular exercise in men with prostate cancer, according to a recent study published by Galvão et al in JAMA Network Open.
Background
Sexual dysfunction is a critical adverse effect of prostate cancer treatment and a major survivorship issue among...
The ASCO Post Staff
/
Friday, March 14, 2025 10:13 AM
Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research.
...
The ASCO Post Staff
/
Monday, March 17, 2025 11:25 AM
A novel treatment approach may improve outcomes in patients with recurrent or metastatic cervical cancer, according to new findings presented by Choi et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.
Recurrent cervical cancer remains a significant challenge,...
The ASCO Post Staff
/
Wednesday, March 19, 2025 11:44 AM
In a paper published in JAMA Oncology, Tilki et al reported that the current standard monitoring of prostate-specific antigen (PSA) following radical prostatectomy—1.5 to 2 months—is too short to accurately identify recurrence and inform treatment decisions. Rather, PSA levels should be measured...
The ASCO Post Staff
/
Thursday, March 20, 2025 11:17 AM
A novel artificial intelligence (AI) tool, called Unfold AI, may help to determine which men with prostate cancer are most likely to benefit from partial gland cryoablation, according to a recent study published by Brisbane et al in BJUI Compass. The findings may play a key role in improving...
The ASCO Post Staff
/
Monday, March 17, 2025 11:13 AM
Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.
Together, the two studies...
The ASCO Post Staff
/
Tuesday, March 25, 2025 10:28 AM
A novel technique designed to improve the precision of prostate cancer surgery could preserve erectile function in nearly twice as many men compared with standard surgery, according to new findings presented by Almeida-Magana et al at the European Association of Urology (EAU) Congress 2025 (
The ASCO Post Staff
/
Tuesday, March 25, 2025 12:00 PM
Biopsies guided by high-resolution ultrasound may be as effective as those using magnetic resonance imaging (MRI) in diagnosing prostate cancer, an international clinical trial has shown. The technology, called micro-ultrasound, is cheaper and easier to use than MRI. It could significantly speed up ...
The ASCO Post Staff
/
Tuesday, March 18, 2025 10:18 AM
Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of...
Matthew Stenger
/
Monday, April 7, 2025 11:50 AM
In a U.K. trial (TRANSLATE) reported in The Lancet Oncology, Bryant et al found that local anesthetic transperineal (LATP) prostate biopsy detected more Gleason Grade Group (GGG) ≥ 2 prostate cancer compared with transrectal ultrasound (TRUS)-guided biopsy in previously biopsy-naive individuals who ...